Adaptive MR-guided whole-pelvic SBRT with or without focal intraprostatic lesion boost for high-risk localized prostate Cancer: Adverse events and longitudinal quality-of-life outcomes. November 2, ...
(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...
This was a retrospective, single-center study conducted at a tertiary referral center between 2007 and 2024. Patients who ...
The 2026 European Society for Medical Oncology (ESMO) Annual Congress held Poster 2279P - ERG-Dependent Prognostic Impact of ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...
(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...
The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...
Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...
The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...
(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results